CLN11 disease is a rare, inherited form of Batten disease, a type of neurodegenerative disorder. It is caused by a mutation in the CLN11 gene, which is responsible for producing a protein called TPP1. People with CLN11 disease experience progressive vision loss, seizures, and cognitive decline. There is currently no cure for CLN11 disease, but treatments are available to help manage symptoms.

CLN11 disease is a rare, inherited disorder that affects the nervous system. Symptoms of CLN11 disease can vary from person to person, but may include:

-Developmental delays

-Seizures

-Movement problems

-Vision and hearing loss

-Cognitive impairment

-Behavioral problems

-Speech and language delays

-Muscle weakness

-Difficulty swallowing

-Gastrointestinal problems

-Skin abnormalities

CLN11 disease is caused by a mutation in the CLN11 gene. This gene is responsible for producing a protein called tripeptidyl peptidase 1 (TPP1). Mutations in this gene lead to a decrease in the amount of TPP1 produced, which can cause a range of neurological symptoms.

Currently, there is no known cure for CLN11 disease. Treatment focuses on managing symptoms and slowing the progression of the disease. Treatment options may include physical therapy, occupational therapy, speech therapy, medications to control seizures, and dietary modifications. Additionally, genetic counseling and support services may be recommended.

The primary risk factor for CLN11 disease is having a family history of the condition. Other risk factors include being of Ashkenazi Jewish descent, having a parent with a CLN11 mutation, and having a sibling with the condition.

At this time, there is no known cure or medications for CLN11 disease. Treatment is focused on managing symptoms and providing supportive care.